Utilization and Effects of Direct Oral Anticoagulants in Atrial Fibrillation Patients Experiencing Cardioembolic Stroke
Overview
Revise to include methodology and clarify the relationship between DOAC adherence and stroke severity.
Background
Atrial fibrillation is a leading cause of cardioembolic strokes, which are associated with increased morbidity and mortality. The use of DOACs has transformed stroke prevention in AF patients, yet non-adherence remains a critical issue, particularly in Eastern Europe. Understanding the implications of DOAC adherence on stroke outcomes is essential for improving patient care and reducing stroke incidence.
Data Highlights
Characteristic
DOAC Users
Non-Users
Mean NIHSS Score
8.84 ± 6.76
11.58 ± 6.98
Mean Left Atrial Volume Index (LAVI)
56.05 ± 19.31
46.94 ± 14.33
Key Findings
43.4% of CES patients with AF were not on anticoagulation therapy prior to the stroke.
Patients on DOACs had significantly milder strokes compared to non-users (mean NIHSS score: 8.84 vs. 11.58).
DOAC users exhibited larger left atrial volume indices (LAVI) than non-users (56.05 vs. 46.94).
55.8% of Latvian AF patients were non-adherent to DOACs, with 30.6% having gaps in therapy.
Adherence to DOACs is linked to a 31% reduction in ischemic stroke risk.
Clinical Implications
Healthcare providers should prioritize adherence to DOAC therapy in AF patients to mitigate the risk of severe strokes. Strategies to enhance patient compliance, such as education and regular follow-ups, are essential in managing AF and preventing cardioembolic strokes.
Conclusion
Reiterate the importance of addressing non-adherence with recommendations for future research.
